Related Experiment Video
Updated: Jul 9, 2026

Near Infrared NIr Light Increases Expression of a Marker of Mitochondrial Function in the Mouse Vestibular Sensory Epithelium
Published on: March 14, 2015
Red-light photobiomodulation improves cognition and neuropsychiatric symptoms in post-stroke cognitive impairment: a
Xuerong Huang1,2,3, Zihui Sun1,4,5, Weijie Wu1
1The Third Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Introduction:
Acute stroke patients often develop post-stroke cognitive impairment (PSCI) and dysthymic disorders. Formaldehyde (FA) induces cognitive decline and depression; while red light (RL) at 630 nm can degrade FA by activating FA-dehydrogenase (FDH). This study investigates the therapeutic effects of a novel RL device on cognitive function and neuropsychiatric symptoms in patients with PSCI.
Methods:
This was an exploratory, parallel-group, randomized controlled trial with concealed allocation, assessor blinding and intention-to-treat analysis. Stroke patients (n = 90) were enrolled. A total of 38 patients in the PSCI group and 44 patients in the PSCI-RL group completed the study. Participants were followed for 6 months, during which the intervention phase comprised 3 months of RL therapy or sham stimulation, followed by continued follow-up. Cognitive [Montreal Cognitive Assessment (MoCA)/Mini-Mental State Examination (MMSE)], neuropsychiatric [Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA)], and functional [Barthel Index (BI)] assessments were conducted at baseline and 6 months. Blood and urine levels of key enzymes and metabolites involved in FA metabolism were quantified, including semicarbazide-sensitive amine oxidase (SSAO, an FA-generating enzyme), FDH (an FA-degrading enzyme), cytochrome c (Cyt-c), FA, hydrogen peroxide (H2O2, a marker of FA generation), and coenzyme Q10 (CoQ10, an endogenous FA scavenger).
Results:
The phototherapy device improved cognitive abilities, reduced anxiety and depression, lessened stroke severity, and enhanced daily living activities in the PSCI-RL group at 6 months. Additionally, RL therapy altered FA metabolism, as it lowered SSAO and H2O2 levels and increased FDH, Cyt-c, and CoQ10 in blood and/or urine of PSCI patients.
Conclusions:
RL therapy may improve clinical symptoms in post-stroke patients by modulating FA metabolism, suggesting a safe and promising approach for treatment and rehabilitation.
Clinical Trial Registration:
https://www.chictr.org.cn/showproj.html?proj=159956, Identifier: ChiCTR2200058991.
Related Concept Videos
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Neuroplasticity

